



**NEWS ANNOUNCEMENT  
CONTACT: SARAH PILBROW**

**FOR IMMEDIATE RELEASE**

**Date: 10.11.09**

**Job number: 681-09**

## **Press release**

**Keywords: Bio-decontamination; HPV systems; HAI**  
**Word count: 229 (including title)**  
**Photograph: BioGienie**

**- copy starts -**

### **New strategic alliance enhances biosecurity in healthcare**

*STERIS and Hygienics Biosecurity join forces to provide a complete range of solutions for infection prevention.*

**BASINGSTOKE, UK – November 11, 2009** – STERIS Ltd has announced a new relationship with Hygienics Biosecurity Ltd to exclusively offer the BioGienie<sup>®</sup> hydrogen peroxide system as part of the STERIS infection prevention range. The BioGienie is a compact, innovative hydrogen peroxide delivery system designed to provide rapid and effective bio-decontamination in the clinical setting. Its Hypoxil Active<sup>™</sup> disinfectant cartridge system provides high levels of bioprotection, while simplifying operation and enhancing user safety. The agreement to supply the BioGienie complements the existing family of STERIS VHP<sup>®</sup> systems, offering a comprehensive range of bio-protection and decontamination solutions for reducing the risk of hospital acquired infections (HAIs), such as those caused by MRSA, *C. difficile*, *E. coli* and norovirus.

Paul Thody, manager of STERIS Professional Services, said of the distribution relationship: "We are delighted to expand our portfolio of infection prevention technologies through our strategic alliance with Hygienics Biosecurity. This technology builds on our strengths in providing world

class bio-decontamination solutions, including our existing VHP technology, to be at the forefront of the fight against HAIs.” He added: “The addition of the BioGenie to our portfolio of bio-decontamination products and services offers healthcare providers greater choice and flexibility for the control of life-threatening pathogens in the clinical environment.”

#### **About STERIS**

STERIS Corporation is a leading provider of infection prevention and surgical products and services, focused primarily on critical healthcare, pharmaceutical and research markets. The Company's more than 5,000 dedicated employees around the world work together to supply a broad array of solutions by offering a combination of equipment, consumables and services that enhance Customer productivity and quality, and help make the world a safer place. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, please visit [www.steris.com](http://www.steris.com).

*This news release may contain statements concerning certain expectations, forecasts, estimates, product performance or other forward-looking information affecting or relating to the Company or its products and services that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this release, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "new," "advanced," and "best available," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in this news release including, without limitation, disruption of production or supplies, changes in product use, pending or future claims, technology advances, and changes in government regulations or the application or interpretation thereof. No assurances can be provided as to any product performance or product safety unless all labeling, instructions for use, MSDS and other product literature are strictly followed. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in this news release include, without limitation, (a) the possibility that market demand will not develop for new technologies, products or applications; (b) the possibility that application of or compliance with laws, court rulings, regulations, certifications or other requirements or standards may delay or prevent product introductions or otherwise affect product performance; or (c) uses not consistent with product instructions. Product descriptions and performances herein are for illustration only and do not modify labeling, warranties or other*

For further information, contact:

Sarah Pilbrow  
STERIS  
STERIS House  
Jays Close  
Viables  
Basingstoke  
Hampshire  
RG22 4AX

Tel: +44 (0)1256 840 400  
Fax: +44 (0)1256 866 503  
Website: [www.STERIS.com](http://www.STERIS.com)

- copy ends -

© 2009 kdm communications limited

**Editorial contact for further information or follow-up**

Sarah Khan at **kdm communications limited**, Bedford, UK

Tel. +44 (0) 1234 210555 Fax: +44 (0) 1234 342397

email [ideas@kdm-communications.com](mailto:ideas@kdm-communications.com)